PHILADELPHIA, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a late-stage clinical biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 11:10 a.m. ET in Boston, MA. A live webcast of the presentation will be available on the News ...

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Tuesday, March 10, 2026, to review fourth-quarter and full-year 2025 financial results. During the conference call and accompanying webcast, senior management will provide an overview of quarterly and full-year financial performance. Investors and other interested parties may access the live audio webcast via ...

SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D., Ph.D., chief executive officer and co-founder of Septerna, will present at the TD Cowen 46th Annual Health Care Conference on Tuesday, March 3, 2026, at 3:10 p.m. ET in Boston. A live webcast of the presentation will be available in the investors section of the compan ...

Artisan Partners, an investment management company, released its fourth-quarter 2025 investor letter for “Artisan Mid Cap Fund”.  A copy of the letter can be downloaded here. The Fund seeks to invest in companies that possess franchise characteristics, with strong earnings trajectories, and are trading at a discount to the estimated private market value. US equities ended a record year with robust fourth-quarter gains. The Fund’s Investor Class, ARTMX, delivered -0.44%, the Advisor Class, APDMX, delivered - ...

Company Overview - Apogee Therapeutics, Inc. is a clinical-stage biotechnology company focused on advancing novel biologics for inflammatory and immune (I&I) markets, including treatments for Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), and Chronic Obstructive Pulmonary Disease (COPD) [3] - The company's lead program, Zumilokibart (APG777), is being developed primarily for AD, which is identified as the largest and least penetrated market within I&I [3] - Apogee aims to achieve best-in-class efficacy and dosing through its antibody programs, which target established mechanisms of action and utilize advanced antibody engineering [3] Upcoming Events - Management will participate in a fireside chat at the TD Cowen 46th Annual Health Care Conference on March 3, 2026, at 9:10 a.m. E.T. [1] - The company will also attend the UBS Biotech Summit Miami on March 9, 2026, and the Jefferies Biotech on the Beach Summit on March 10, 2026 [1] Investor Relations - For investor inquiries, Noel Kurdi serves as the VP of Investor Relations at Apogee Therapeutics [4] - Media inquiries can be directed to Dan Budwick at 1AB [4]

treatment of psoriasis, there can be no assurance as to the timing or success of the clinical trials of SGX302 for the treatment of psoriasis. Additionally, despite the biologic activity observed in aphthous ulcers induced by chemotherapy and radiation, there can be no assurance as to the timing or success of the clinical trials of SGX945 for the treatment of Behçet's Disease. Further, there can be no assurance that RiVax® will qualify for a biodefense Priority Review Voucher (PRV) or that the prior sales o ...

PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over- year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its. ...

Core Insights - Artisan Mid Cap Fund's fourth-quarter 2025 performance showed a decline, with Investor Class at -0.44%, Advisor Class at -0.37%, and Institutional Class at -0.35%, compared to -3.70% for the Russell Midcap® Growth Index, indicating relative resilience in a challenging market [1]. Group 1: Fund Performance - The Fund seeks investments in companies with franchise characteristics, strong earnings trajectories, and trading at a discount to estimated private market value [1]. - Continued strength in information technology and health care sectors contributed positively to the Fund's performance during the quarter [1]. Group 2: Insmed Incorporated (NASDAQ:INSM) - Insmed Incorporated specializes in therapies for serious and rare diseases, with a market capitalization of $33.917 billion [2]. - The stock closed at $159.03 per share on February 23, 2026, with a one-month return of -2.22% and a 52-week gain of 105.20% [2]. - Insmed was a top contributor to the Fund's performance in Q4, driven by strong sales of its lead product ARIKAYCE® and the successful launch of Brinsupri™, which generated $28 million in initial sales [3]. Group 3: Hedge Fund Interest - Insmed was held by 74 hedge fund portfolios at the end of Q4, an increase from 73 in the previous quarter, indicating growing interest among institutional investors [4]. - Despite its potential, the company is not among the 30 most popular stocks among hedge funds, with some analysts suggesting that certain AI stocks may offer greater upside potential [4].

Earlier on January 27, Matt Stucky from Northwestern Mutual joined CNBC’s ‘Closing Bell Overtime’ to discuss a shifting market landscape where investor focus is broadening beyond mega-cap stocks. Stucky observed that earnings revisions are beginning to improve across various sectors, including small caps, which is helping to unlock value dislocations that have accumulated over the last three years. He argued that for small-cap outperformance to continue, the market needs to see consistent upward earnings re ...

New Program Designed as Platform-based Approach for Direct Correction of Mutations Causing PKU; Investigational New Drug (IND) Filing for BEAM‑304 Anticipated in 2026 Updated Phase 1/2 Data and Next Steps for Pivotal Development for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) on Track for Q1 2026 Strategic Financing Agreement with Sixth Street Provides up to $500 Million in Long-term, Non-dilutive Capital to Fund Anticipated Launch of Risto-cel in Sickle Cell Disease (SCD); U.S. Biologics License Appl ...